<DOC>
	<DOCNO>NCT00121433</DOCNO>
	<brief_summary>The purpose trial determine injection leptin would improve vascular function normal-weight , healthy volunteer .</brief_summary>
	<brief_title>Leptin Endothelial Function</brief_title>
	<detailed_description>The researcher plan enroll total 15 non-obese ( BMI &lt; 27 kg/m2 ) otherwise healthy adult randomize , double-blinded , cross-over study impact recombinant methionyl human leptin 0.2 mg/kg SC , hereafter call rL , ( Amgen Inc , Thousand Oaks , Calif ) versus placebo SC ( sorbitol sodium acetate , pH 4.0 volume ) 15 non-obese adult . Subjects baseline vascular study perform brachial artery ultrasonography-flow-mediated dilatation nitroglycerin mediate dilatation blood drawn measure leptin level . They receive rL SC placebo SC ( randomize order ) . They vascular study perform blood level draw every 2 hour 6 hour total . After completion day 1 , patient return 1-4 week later repeat protocol crossed-over alternate intervention ( rL placebo ) .</detailed_description>
	<criteria>Healthy male female age 1850 . BMI &lt; 27 kg/m2 lean group Any CVD risk factor ( diabetes fast glucose &gt; 126 mg/dL Hypertension measure BP &gt; 140/90 mmHg Current tobacco smoking within last month LDL &gt; 160 mg/dL , HDL &lt; 35 mg/dL ) Renal insufficiency ( creatinine &gt; 1.4 mg/dL ) Thyroid abnormality ( abnormal TSH ) Established CVD ( atherosclerosis , history peripheral arterial disease , previous stroke , myocardial infarction , angina , heart failure , aortic aneurysm ) Usage medication impact endothelial function within last month ( folate , fish oil , Vitamin C E , Larginine , blood pressure lipidlowering medication , diabetes medication )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>